Literature DB >> 9072550

Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.

K Waldeck1, B Larsson, K E Andersson.   

Abstract

PURPOSE: To compare in vitro the antimuscarinic effect of oxybutynin and its active metabolite, N-desethyl-oxybutynin, on human detrusor, and their binding characteristics in detrusor and parotid gland.
MATERIALS AND METHODS: Antimuscarinic effect in the detrusor was assessed as the ability of the drugs to inhibit carbachol-induced contractions and contractions induced by electrical nerve stimulation. In addition, the drugs' ability to displace 3H-QNB from muscarinic receptors was investigated.
RESULTS: Both oxybutynin and N-desethyl-oxybutynin caused a rightward shift of the concentration-response curve for carbachol without depression of the maximum, indicating a competitive antagonism. The pA2 values were 7.8 for oxybutynin and 7.6 for N-desethyl-oxybutynin. Contractions induced by electrical nerve stimulation were depressed by 87% by oxybutynin (10 microM) and by 91% by N-desethyl-oxybutynin (10 microM). In radioligand receptor binding studies on the detrusor, oxybutynin and N-desethyl-oxybutynin had uniform displacement curves and the same pKi value, 8.2. The affinity for N-desethyl-oxybutynin in the parotid gland was significantly higher, the pKi value being 8.7. The corresponding figure for oxybutynin was 8.5.
CONCLUSIONS: We conclude that oxybutynin and N-desethyl-oxybutynin have a similar antimuscarinic effect in the human detrusor, and the same binding characteristics in detrusor and parotid gland, respectively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9072550

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  44 in total

1.  Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.

Authors:  Roger R Dmochowski; Victor Nitti; David Staskin; Karl Luber; Rodney Appell; G Willy Davila
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

2.  Transdermal systems for overactive bladder: principles and practice.

Authors:  David R Staskin
Journal:  Rev Urol       Date:  2003

3.  Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence.

Authors:  R A Appell
Journal:  Rev Urol       Date:  2001

Review 4.  Update on overactive bladder: pharmacologic approaches on the horizon.

Authors:  Eric S Rovner; Alan J Wein
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 3.092

5.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

Review 6.  Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

Authors:  Martin C Michel; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11       Impact factor: 3.000

7.  Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.

Authors:  Gary G Kay; David R Staskin; Scott MacDiarmid; Marilyn McIlwain; Naomi V Dahl
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

8.  Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.

Authors:  Tomomi Oki; Shuichi Sato; Keiji Miyata; Shizuo Yamada
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 9.  A benefit-risk assessment of extended-release oxybutynin.

Authors:  Martin C Michel
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.

Authors:  Scott A Macdiarmid
Journal:  Rev Obstet Gynecol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.